Most benefit of RSLV-132 seen in patients with more active SLE
RSLV-132 failed to lessen damage caused by skin lesions in SLE in a trial, but tended to ease symptoms in patients with more active disease.| Lupus News Today
RSLV-132 failed to lessen damage caused by skin lesions in SLE in a trial, but tended to ease symptoms in patients with more active disease.| Lupus News Today
A CAR T-cell therapy cleared disease-causing autoantibodies from the bloodstream of eight SLE patients without compromising vaccine response.| Lupus News Today
Author archive page for Lindsey Shapiro.| Lupus News Today
Scientist Akiko Iwasaki will receive award to investigate whether ancient viral DNA in our cells is a potential trigger for lupus.| Lupus News Today
